Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-21
2011-06-21
Ton, Thaian N. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S468000, C435S455000
Reexamination Certificate
active
07964571
ABSTRACT:
Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
REFERENCES:
patent: 6696038 (2004-02-01), Mahato et al.
patent: 2004/0142474 (2004-07-01), Mahato et al.
patent: WO 02/22174 (2002-03-01), None
patent: WO 02/22174 (2002-03-01), None
patent: WO 03/008555 (2003-01-01), None
Goverdhana et al, Molecular Therapy, 12(2): 189-211, 2005.
Salem, et al, Journal of Interferon & Cytokine Research, 26: 593-608, 2006.
Li et al, Gene Therapy, 13: 1313-1319, 2006.
Janat et al, Proc Am Soc Clin Oncol, May 31, 2003, 22: abstract 933.
Jia et al, Clinical Cancer Research, 9: 3462-3468, 2003.
Roth et al, Annu Rev Biomed Eng, 397-426, 2004.
Anwer et al, (Cancer Gene Therapy, 7(8): 1156-1164, 2000.
Han et al, (Molecular Therapy, 2(4): 302-317, 2000.
Voskoglou-Nomikos et al (Clinical Cancer Research, 9: 4227-4239, 2003.
Kelland et al (European Journal of Cancer, 40: 827-836, 2004.
Kerbel et al (Cancer Biology & Therapy 2: 4 suppl. 1, S134-139, 2003.
Prieto et al, (Expert Opin Biol Ther, 4(7): 1073-1091, 2004.
Ohlfest et al, (Current Gene Therapy, 5: 629-641, 2005.
Meyers et al, (JBC, 273(25): 15621-15627, 1998).
Fidler et al (Cancer Metastasis Rev. 10(3): 229-43, 1991).
Hambardzumyan et al, (Expert Opin Drug Discov, 2(11):1435-1451, 2007).
Carrion et al (Chemistry and Physics of Lipids, 113: 97-110, 2001).
Liu et al (J. Biol. Chem, 270: 24864-24870, 1995).
Dow et al (Human Gene Therapy, 10: 2961-2972, 1999).
Hong et al (FEBS Lett. 400(2):233-7, 1997).
Lee et al, (Gene Ther, (13): 859-66, 2002).
Lesage et al, (Biochimica et Biophysica Acta (BBA)—Biomembranes, 1564(2): 393-402, 2002).
Merdan, Thomas, et al., Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug. Chem., 2003, vol. 14, pp. 989-996.
Chiu et al. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release. 2004, vol. 97, pp. 357-369.
Aigner et al. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. 2002, vol. 9, pp. 1700-1707.
Daqing, Li et al, “Combination Nonviral Interleukin 2 and Interleukin 12 Gene Therapy for Head and Neck Squamous Cell Carcinoma,”Arch. Otolaryngol Head Neck Surg, 2001, vol. 127, 1319-1324.
Anwer, Khursheed et al., “Cationic Lipid-based Delivery System for Systemic Cancer Gene Therapy,” Cancer Gene Ther. 2000, vol. 7, 1156-1164.
Zagozdzon, Radoslaw et al., “The Potentiated Antileukemic Effects of Doxorubicin and Interleukin-12 Combination are Not Dependent on Nitric Oxide Production,” Cancer Lett., 1999, vol. 147, 67-75.
Daqing, Li et al. “Interleukin 2 Gene Transfer Prevents NKG2D Suppression and Enhances Antitumor Efficacy in Combination with Cisplatin for Head and Neck Squamous Cell Cancer,” Cancer Res., 2002, vol. 62, 4023-4028.
Teicher, Beverly A. et al., “Optimal Scheduling of Interleukin 12 and Chemotherapy in the Murine MB-49 Bladder Carcinoma and B16 Melanoma,” Clin. Cancer Res., 1997, vol. 3, 1661-1667.
Lenzi, Renato et al., “Phase I Study of Intraperitoneal Recombinant Human Interleukin 12 in Patients with Mullerian Carcinoma, Gastrointestinal Primary Malignancies, and Mesothelioma,” Clin. Cancer Res., 2002, vol. 8, 3686-3695.
Davis, Mark E., “Non-Viral Gene Delivery Systems,” Curr Opin Biotechnol, 2002, vol. 13, 128-131.
Wei, M.Q. et al. “Sustained Gene Expression in Transplanted Skin Fibroblasts in Rats” Gene Ther. 1999, vol. 6, 840-844.
Schuh, Theda et al., “DNA-Based Vaccine Against La Crosse Virus: Protective Immune Response Mediated by Neutralizing Antibodies and CD4+T Cells,” Gene Ther., 1999, vol. 10, 1649-1658.
Mendiratta, Sanjeev K. et al., “Combination of Interleukin 12 and Interferon α Gene Therapy Induces a Synergistic Antitumor Response against Colon and Renal Cell Carcinoma,” Gene Ther., 2000, vol. 11, 1851-1862.
Maruyama-Tabata, H. et al., “Effective Suicide Gene Therapy in Vivo by EBV-based Plasmid Vector Coupled with Polyamidoamine Dendrimer,” Gene Ther., 2000, vol. 7, 53-60.
Maheshwari, A. et al., “Biodegradable Polymer-based Interleukin-12 Gene Delivery: Role of Induced Cytokines, Tumor Infiltrating Cells and Nitric Oxide in Anti-Tumor Activity,” Gene Ther., 2002, vol. 9, 1075-1084.
Nakanishi, H. et al., “Nonviral Genetic Transfer of Fas Ligand Induced Significant Growth Suppression and Apoptotic Tumor Cell Death in Prostate Cancer in Vivo,” Gene Ther., 2003, vol. 10, 434-442.
Coleman, Mike et al., “Nonviral Interferon α Gene Therapy Inhibits Growth of Established Tumors by Eliciting a Systemic Immune Response,” Hum Gene Ther., 1998, vol. 9, 2223-2230.
Zagozdzon, Radoslaw et al., “Effective Chemo-Immunotherapy of L1210 Leukemia In Vivo Using Interleukin-12 Combined with Doxorubicin but not with Cyclophosphamide, Paclitaxel or Cisplatin,” Int. J. Cancer, 1998, vol. 77, 720-727.
Yockman, James W. et al., “Tumor Regression by Repeated Intratumoral Delivery of Water Soluble Lipopolymers/p2CMVmIL-12 Complexes”, J. Control Release 2003, vol. 87, 177-186.
Tsung, Kangla et al., “Immune Response Against Large Tumors Eradicated by Treatment with Cyclophosphamide and IL-12,” J. Immunol., 1998, vol. 160, 1369-1377.
Tare, Nadine S. et al., “Administration of Recombinant Interleukin-12 to Mice Suppresses Hematopoiesis in the Bone Marrow but Enhances Hematopoiesis in the Spleen,” J. Interferon Cytokine Res., 1995, vol. 15, 377-383.
Sarmiento, Ulla M. et al, “Biologic Effects of Recombinant Human Interleukin-12 in Squirrel Monkeys,” Lab Invest., 1994, vol. 71, 862-873.
Daqing, Li et al., “Combination Nonviral Cytokine Gene Therapy for Head and Neck Cancer,” Laryngoscope 2001, vol. 111, 815-820.
Mahato, Ram. I et al., “Intratumoral Delivery of p2CMVmIL-12 Using Water-Soluble Lipopolymers,” Molecular Therapy, 2001, vol. 4, 130-138.
Janat-Amsbury, Margit Maria, et al. “Combination of Local, Nonviral IL12 Gene Therapy and Systemic Paclitaxel Treatment in a Metastatic Breast Cancer Model,” Molecular Therapy, 2004, vol. 9, 829-836.
Gerson, Stanton L., “MGMT: Its Role in Cancer Aetiology and Cancer Therapeutics,” Nature Reviews Cancer 2004, vol. 4, 296-307.
Ridge, John Paul et al., “A Conditioned Dendritic Cell Can be a Temporal Bridge Between a CD4+T-helper and a T-killer Cell,” Nature, 1998, vol. 393, 474-477.
Bennett, Sally R.M. et al., “Help for Cytotoxic-T-cell Responses is Mediated by DC40 Signalling,” Nature, 1998, vol. 393, 478-480.
Schoenberger, Stephen P. et al., “T-cell Help for Cytotoxic T Lymphocytes is Mediated by CD40-CD40L Interactions,” Nature, 1998, vol. 393, 480-483.
Cohen, Jon, “IL-12 Deaths: Explanation and a Puzzle,” Science, 1995, vol. 270, 1-2.
Robertson, Michael J. et al., “Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment,” The Oncologist, 1996, vol. 1, 88-97.
Anwer, Khursheed et al., “Recent Progress in Polymeric Gene Delivery Systems,” Critical Reviews™ in Therapeutic Drug Carrier Systems, 2003, vol. 20 (4), 249-293.
Furgeson, et al.,Tumor efficacy and 1-38 biodistribution of linear polyethylenimine-cholesterol/DNA complexes, Molecular Therapy, 9:837-845 (2004).
Fewell, et al.,Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer, Journal of Controlled Release, 109:288-298 (2005).
Anwer Khursheed
Fewell Jason G.
Lewis Danny H.
Matar Majed
Rice Jennifer
Egen, Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Sgagias Magdalene
Ton Thai-an N.
LandOfFree
Combination of immuno gene therapy and chemotherapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of immuno gene therapy and chemotherapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of immuno gene therapy and chemotherapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638437